These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 4092726)

  • 1. Pharmacokinetics of carteolol in relation to renal function.
    Hasenfuss G; Schäfer-Korting M; Knauf H; Mutschler E; Just H
    Eur J Clin Pharmacol; 1985; 29(4):461-5. PubMed ID: 4092726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and absolute bioavailability of carteolol, a new beta-adrenergic receptor blocking agent.
    Ishizaki T; Ohnishi A; Sasaki T; Kushida K; Horai Y; Chiba K; Suganuma T
    Eur J Clin Pharmacol; 1983; 25(1):95-101. PubMed ID: 6137389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of carteolol in patients with impaired renal function.
    Amemiya M; Tabei K; Furuya H; Sakairi Y; Asano Y
    Eur J Clin Pharmacol; 1992; 43(4):417-21. PubMed ID: 1451723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of hydrochlorothiazide in relation to renal function.
    Niemeyer C; Hasenfuss G; Wais U; Knauf H; Schäfer-Korting M; Mutschler E
    Eur J Clin Pharmacol; 1983; 24(5):661-5. PubMed ID: 6873147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Animal experimental studies on the pharmacokinetics of carteolol].
    Lang W
    Arzneimittelforschung; 1983; 33(2a):286-9. PubMed ID: 6682319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Butofilolol pharmacokinetics in chronic renal insufficiency.
    Jeanniot JP; Houin G; Ledudal P; Cautreels W; Giudicelli CP; Tillement JP
    Int J Clin Pharmacol Res; 1984; 4(3):165-73. PubMed ID: 6149194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of carteolol on renal function in healthy subjects and patients with hypertension.
    Tabei K; Furuya H; Asano Y; Hosoda S
    Eur J Clin Pharmacol; 1989; 36(1):83-6. PubMed ID: 2917595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal hemodynamics and pharmacokinetics of bevantolol in patients with impaired renal function.
    Solimon M; Massry SG; Campese VM
    Am J Cardiol; 1986 Nov; 58(12):21E-24E. PubMed ID: 2878596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic fate of carteolol hydrochloride, (OPC-1085) VIII, a new beta-adrenergic blocking agent. Pharmacokinetic studies of carteolol in man.
    Morita S; Iinuma M; Kido M; Sakuragi S; Kohri H; Nishino H
    Arzneimittelforschung; 1977; 27(12):2380-3. PubMed ID: 23800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.
    Kirch W; Rose I; Demers HG; Leopold G; Pabst J; Ohnhaus EE
    Clin Pharmacokinet; 1987 Aug; 13(2):110-7. PubMed ID: 2887325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function.
    Takabatake T; Ohta H; Maekawa M; Yamamoto Y; Ishida Y; Hara H; Nakamura S; Ushiogi Y; Kawabata M; Hashimoto N
    Eur J Clin Pharmacol; 1985; 28(3):327-31. PubMed ID: 2861096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, pharmacology of atenolol and effect of renal disease.
    Wan SH; Koda RT; Maronde RF
    Br J Clin Pharmacol; 1979 Jun; 7(6):569-74. PubMed ID: 465278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment.
    Rosenkranz B; Profozic V; Metelko Z; Mrzljak V; Lange C; Malerczyk V
    Diabetologia; 1996 Dec; 39(12):1617-24. PubMed ID: 8960852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and dosage adjustment of cefotiam in renal impaired patients.
    Rouan MC; Binswanger U; Bammatter F; Theobald W; Schoeller JP; Guibert J
    J Antimicrob Chemother; 1984 Jun; 13(6):611-8. PubMed ID: 6088464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
    Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
    Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elimination of nadolol by patients with renal impairment.
    Herrera J; Vukovich RA; Griffith DL
    Br J Clin Pharmacol; 1979; 7 Suppl 2(Suppl 2):227S-231S. PubMed ID: 37878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment.
    Halstenson CE; Triscari J; DeVault A; Shapiro B; Keane W; Pan H
    J Clin Pharmacol; 1992 Feb; 32(2):124-32. PubMed ID: 1613121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function.
    Nilsen OG; Saltvedt E; Walstad RA; Marstein S
    Am J Med; 1992 Apr; 92(4A):38S-40S. PubMed ID: 1316068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single- and multiple-dose pharmacokinetics, kidney tolerability and plasma protein binding of tenoxicam in renally impaired patients and healthy volunteers.
    Nilsen OG; Aasarød K; Widerøe TE; Guentert TW
    Pharmacol Toxicol; 2001 Nov; 89(5):265-72. PubMed ID: 11881981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of renal function on the pharmacokinetics of unchanged and acyl-glucuroconjugated ketoprofen enantiomers after 50 and 100 mg racemic ketoprofen.
    Skeith KJ; Dasgupta M; Lange R; Jamali F
    Br J Clin Pharmacol; 1996 Aug; 42(2):163-9. PubMed ID: 8864313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.